Cargando…

Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light

The purpose of the present study was to evaluate changes of signs and symptoms in patients with meibomian gland dysfunction (MGD) treated with intense regulated pulsed light (IRPL), and to further investigate which parameter could predict positive outcomes of the procedure. Twenty-eight patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Vigo, Luca, Taroni, Leonardo, Bernabei, Federico, Pellegrini, Marco, Sebastiani, Stefano, Mercanti, Andrea, Di Stefano, Nicola, Scorcia, Vincenzo, Carones, Francesco, Giannaccare, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963914/
https://www.ncbi.nlm.nih.gov/pubmed/31614910
http://dx.doi.org/10.3390/diagnostics9040147
_version_ 1783488391750352896
author Vigo, Luca
Taroni, Leonardo
Bernabei, Federico
Pellegrini, Marco
Sebastiani, Stefano
Mercanti, Andrea
Di Stefano, Nicola
Scorcia, Vincenzo
Carones, Francesco
Giannaccare, Giuseppe
author_facet Vigo, Luca
Taroni, Leonardo
Bernabei, Federico
Pellegrini, Marco
Sebastiani, Stefano
Mercanti, Andrea
Di Stefano, Nicola
Scorcia, Vincenzo
Carones, Francesco
Giannaccare, Giuseppe
author_sort Vigo, Luca
collection PubMed
description The purpose of the present study was to evaluate changes of signs and symptoms in patients with meibomian gland dysfunction (MGD) treated with intense regulated pulsed light (IRPL), and to further investigate which parameter could predict positive outcomes of the procedure. Twenty-eight patients who bilaterally received three IRPL sessions at day 1, 15, and 45 satisfied the criteria and were included in the study. Non-invasive break-up time (NIBUT), lipid layer thickness (LLT), meibography, tear osmolarity, and ocular discomfort symptoms were measured before and 30 days after the last IRPL session. Qualified or complete success was defined in the presence of an improvement of symptoms associated with an increase of NIBUT (< or ≥ 20%). After IRPL treatment, median NIBUT and LLT increased from 7.5 to 10.2 s and 2.0 to 3.0, respectively (p <0.001); tear osmolarity decreased from 304.0 to 301.0 mOsm/L (p = 0.002). Subjective symptoms improved after IRPL in 26 patients. Qualified success was reached in 34 eyes, while complete success in 16 eyes. Patients with lower baseline break-up time (BUT) values showed better response to treatment (p = 0.04). In conclusion, IRPL improved signs and symptoms in MGD patients, while lower baseline NIBUT values were predictive of better response to IRPL.
format Online
Article
Text
id pubmed-6963914
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69639142020-01-27 Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light Vigo, Luca Taroni, Leonardo Bernabei, Federico Pellegrini, Marco Sebastiani, Stefano Mercanti, Andrea Di Stefano, Nicola Scorcia, Vincenzo Carones, Francesco Giannaccare, Giuseppe Diagnostics (Basel) Article The purpose of the present study was to evaluate changes of signs and symptoms in patients with meibomian gland dysfunction (MGD) treated with intense regulated pulsed light (IRPL), and to further investigate which parameter could predict positive outcomes of the procedure. Twenty-eight patients who bilaterally received three IRPL sessions at day 1, 15, and 45 satisfied the criteria and were included in the study. Non-invasive break-up time (NIBUT), lipid layer thickness (LLT), meibography, tear osmolarity, and ocular discomfort symptoms were measured before and 30 days after the last IRPL session. Qualified or complete success was defined in the presence of an improvement of symptoms associated with an increase of NIBUT (< or ≥ 20%). After IRPL treatment, median NIBUT and LLT increased from 7.5 to 10.2 s and 2.0 to 3.0, respectively (p <0.001); tear osmolarity decreased from 304.0 to 301.0 mOsm/L (p = 0.002). Subjective symptoms improved after IRPL in 26 patients. Qualified success was reached in 34 eyes, while complete success in 16 eyes. Patients with lower baseline break-up time (BUT) values showed better response to treatment (p = 0.04). In conclusion, IRPL improved signs and symptoms in MGD patients, while lower baseline NIBUT values were predictive of better response to IRPL. MDPI 2019-10-13 /pmc/articles/PMC6963914/ /pubmed/31614910 http://dx.doi.org/10.3390/diagnostics9040147 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Vigo, Luca
Taroni, Leonardo
Bernabei, Federico
Pellegrini, Marco
Sebastiani, Stefano
Mercanti, Andrea
Di Stefano, Nicola
Scorcia, Vincenzo
Carones, Francesco
Giannaccare, Giuseppe
Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light
title Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light
title_full Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light
title_fullStr Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light
title_full_unstemmed Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light
title_short Ocular Surface Workup in Patients with Meibomian Gland Dysfunction Treated with Intense Regulated Pulsed Light
title_sort ocular surface workup in patients with meibomian gland dysfunction treated with intense regulated pulsed light
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963914/
https://www.ncbi.nlm.nih.gov/pubmed/31614910
http://dx.doi.org/10.3390/diagnostics9040147
work_keys_str_mv AT vigoluca ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT taronileonardo ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT bernabeifederico ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT pellegrinimarco ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT sebastianistefano ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT mercantiandrea ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT distefanonicola ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT scorciavincenzo ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT caronesfrancesco ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight
AT giannaccaregiuseppe ocularsurfaceworkupinpatientswithmeibomianglanddysfunctiontreatedwithintenseregulatedpulsedlight